Tag: IFPMA Statement

EB 144 agenda item 5.5 Universal health coverage
EB 144 agenda item 6.1 Pandemic Influenza Preparedness Framework
EB 144 IFPMA statement under agenda item 5.8.2 Non-Communicable Diseases
EB 144 agenda item 5.7, “Technical” Report on Cancer Pricing
EB 144 IFPMA statement under agenda item 5.7, Access to Medicines and Vaccines Roadmap
R&D-based biopharmaceutical industry welcomes UN Declaration on NCDs
R&D-based biopharmaceutical industry welcomes UN Declaration on TB
WHO WHA 70 agenda item 15.6 Cancer prevention and control in the context of an integrated approach
WHO WHA 70 item 13.6 Member State mechanism on SSFFC
WHO WHA 70 agenda item 13.3 Addressing the global shortage of, and access to, medicines and vaccines
WHO WHA 70 Item A70/12 Antimicrobial resistance
IFPMA Statement on Appointment of Dr Tedros as Director-General of the World Health Organization
WHO EB 140, Item 10.2, Draft global action plan on the public health response to dementia
WHO EB140 agenda item 8.6 Member State mechanism on substandard/spurious/ falsely-labelled/falsified/counterfeit medical products
WHO EB 140, Item 7.4, Public Health implications of the implementation of the Nagoya Protocol
WHO EB 140, Item 8.3, Addressing the global shortage of medicines and vaccines
IFPMA statement on the entry in force of the TRIPS “Paragraph 6” amendment
Extension of TRIPS implementation deadline for LDCs
Adoption of the sustainable development goals (SDGs)
WHA 68, Item 15.1 Antimicrobial resistance
WHA 68, Item 17.3, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products
LDCs request for extension of TRIPS implementation
WHO Executive Board 136 - Item 9.4, 2014 Ebola virus disease outbreak
WHO EB 136, Item 8.1, antimicrobial resistance
WHO EB 136, Item 5.1, Framework of engagement with non-State actors
WHO EB 136, Item 9.3, Global Vaccine Action Plan
IFPMA statement in support of 2015 Gavi replenishment

Other Tags

Access Access to antiretrovirals Access to Medicines Access to vaccines Africa AMR AMR Industry Alliance Anti-Counterfeit Antibiotics antimicrobial resistance Assembly Biosimilars Biotherapeutic Medicines Biotherapeutics Cancer Code of Practice collaboration Counterfeit Medicines Counterfeits Developing World Donations Economic footprint Efficacy Ethics; Code; Business integrity; Compliance Event Highlights Fake Medicines Fakes Fight the Fakes Flu Global Health harmonization Health Health Partnerships HIV/AIDS IFPMA IFPMA Assembly IFPMA Geneva Pharma Forum IFPMA Statement Immunization Incremental Innovation Influenza Influenza Vaccination Infographic Infographics Innovation Innovation ecosystem IP IVS Latin America Latin America Conference Malaria MDGs Medicines Mental and Neurological Disorders Millennium Development Goals NCD NCDs Neglected Tropical Diseases News Releases Non-Communicable Diseases NTDs Pandemic Influenza Pandemic preparedness partnership Partnerships Pharma Pharmacovigilance Position Paper Prevention PSI Publications Public Health Quality R&D Regulatory regulatory systems Regulatory System Strengthening Related Links Research Safety SDGs Seasonal Influenza Statements Supply chain Sustainable Development Goals Sustainable Innovation trade Treatments Tuberculosis UHC Universal Health Coverage Vaccine Vaccines Vaccine Supply Value of Innovation Videos WHA WHO WIPO Women’s Cancers